Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nissan Chemical Corporation (4021.T)
Tokyo, JP
Founded in Tokyo in 1887, Nissan Chemical Corporation conducts its diverse business operations both domestically in Japan and across international markets, specializing in four key areas: chemicals, performance materials, agricultural chemicals, and pharmaceuticals. The company's expansive chemical product line includes the adhesive agent MELAMINE, a variety of high-purity chemicals, the urea solution AdBlue, and foundational industrial compounds such as ammonia, sulfuric acid, and nitric acid. Other specialized chemical offerings feature TEPIC (an epoxy compound), Melamine Cyanurate (a salt of melamine and isocyanuric acid), phenylphosphonic acid, and HI-LITE (a chlorinated isocyanurate). Additionally, Nissan Chemical manufactures the health food Nissan Reishi, OPTBEADS (composed of melamine-formaldehyde resin and silica), and FINEOXOCOL (a saturated fatty alcohol and acid). Within its performance materials division, the corporation develops crucial materials for display technologies, semiconductors, and various inorganic applications. Its agricultural chemicals segment supplies a broad range of products, including herbicides, insecticides, and fungicides, utilized on farmlands, golf courses, and public parks. This division also produces active pharmaceutical ingredients for animal antiparasitic medications. In the pharmaceutical sector, Nissan Chemical markets prescription drugs such as LIVALO, which is used to reduce cholesterol, and LANDEL and FINTE, both dual-action calcium channel blockers. Beyond its proprietary pharmaceutical products, the company offers custom manufacturing and process research services for pharmaceutical ingredients. Looking towards future innovation, Nissan Chemical is actively engaged in developing solutions across healthcare, information and communication materials, and environmental and energy materials. The company, which was previously known as Nissan Chemical Industries, Ltd., officially changed its name to Nissan Chemical Corporation in July 2018.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +4.43% | +10.13% | +4.91% | +41.24% | +39.39% | +74.98% | +22.83% | +29.00% | +131.91% | +1,391.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+11.2% ★ Q1'26: +10.0% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+17.6% ★ Q1'26: +31.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+15.8% Q1'26: +7.1% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+22.7% ★ Q1'26: +22.1% (vs Q1'25)
-
ROIC Chemicals: +3.4%+18.6% ★ Q1'26: +21.8% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-1.8% ★ Q1'26: -1.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.49× ★ Q1'26: 0.42× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 9 EPS Ana. |
Mar 2027 3 Rev. Ana. 7 EPS Ana. |
Mar 2028 8 Rev. Ana. 8 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
171.21B
est: 171.78B (-0.3%)
|
176.89B
est: 183.03B (-3.3%)
|
180.29B
est: 181.52B (-0.7%)
|
193.39B
est: 191.70B (+0.9%)
|
204.90B
est: 204.06B (+0.4%)
|
206.84B
est: 206.44B (+0.2%)
|
209.12B
est: 209.55B (-0.2%)
|
207.97B
est: 210.03B (-1.0%)
|
228.07B
est: 227.49B (+0.3%)
|
226.71B
est: 230.45B (-1.6%)
|
251.37B
est: 246.25B (+2.1%)
|
275.20B
266.12B – 278.44B
+11.8% YoY
|
292.36B
289.27B – 297.02B
+6.2% YoY
|
304.93B
286.89B – 328.51B
+4.3% YoY
|
325.70B
314.13B – 341.15B
+6.8% YoY
|
343.40B
331.20B – 359.69B
+5.4% YoY
|
| EBITDA |
33.80B
est: 50.27B (-32.8%)
|
38.29B
est: 53.56B (-28.5%)
|
40.33B
est: 53.12B (-24.1%)
|
45.50B
est: 56.10B (-18.9%)
|
48.01B
est: 59.72B (-19.6%)
|
49.19B
est: 60.41B (-18.6%)
|
52.96B
est: 61.32B (-13.6%)
|
61.18B
est: 61.46B (-0.5%)
|
63.26B
est: 66.57B (-5.0%)
|
62.00B
est: 65.04B (-4.7%)
|
71.21B
est: 69.50B (+2.5%)
|
77.67B
75.11B – 78.58B
+11.8% YoY
|
82.51B
81.64B – 83.83B
+6.2% YoY
|
86.06B
80.97B – 92.71B
+4.3% YoY
|
91.92B
88.66B – 96.28B
+6.8% YoY
|
96.92B
93.48B – 101.51B
+5.4% YoY
|
| EBIT |
25.35B
est: 41.16B (-38.4%)
|
28.61B
est: 43.85B (-34.8%)
|
31.44B
est: 43.49B (-27.7%)
|
34.99B
est: 45.93B (-23.8%)
|
37.09B
est: 48.90B (-24.1%)
|
38.65B
est: 49.46B (-21.9%)
|
42.53B
est: 50.21B (-15.3%)
|
50.96B
est: 50.32B (+1.3%)
|
52.28B
est: 54.51B (-4.1%)
|
48.20B
est: 52.56B (-8.3%)
|
56.83B
est: 56.16B (+1.2%)
|
62.76B
60.69B – 63.50B
+11.8% YoY
|
66.68B
65.97B – 67.74B
+6.2% YoY
|
69.54B
65.43B – 74.92B
+4.3% YoY
|
74.28B
71.64B – 77.80B
+6.8% YoY
|
78.32B
75.54B – 82.03B
+5.4% YoY
|
| Net Income |
18.20B
est: 15.89B (+14.5%)
|
22.35B
est: 19.84B (+12.7%)
|
24.03B
est: 20.72B (+15.9%)
|
27.14B
est: 25.31B (+7.2%)
|
29.37B
est: 27.82B (+5.6%)
|
30.78B
est: 28.47B (+8.1%)
|
33.47B
est: 30.84B (+8.5%)
|
38.78B
est: 36.55B (+6.1%)
|
41.09B
est: 41.12B (-0.1%)
|
38.03B
est: 37.39B (+1.7%)
|
43.04B
est: 41.16B (+4.6%)
|
49.71B
44.85B – 50.37B
+20.8% YoY
|
50.28B
49.80B – 50.76B
+1.2% YoY
|
52.93B
50.45B – 58.91B
+5.3% YoY
|
60.00B
59.70B – 66.45B
+13.3% YoY
|
65.34B
62.33B – 69.37B
+8.9% YoY
|
| SGA |
21.03B
est: 35.05B (-40.0%)
|
22.10B
est: 37.34B (-40.8%)
|
23.10B
est: 37.03B (-37.6%)
|
24.03B
est: 39.11B (-38.6%)
|
26.68B
est: 41.63B (-35.9%)
|
25.29B
est: 42.12B (-39.9%)
|
25.13B
est: 42.75B (-41.2%)
|
30.26B
est: 42.85B (-29.4%)
|
33.61B
est: 46.41B (-27.6%)
|
34.93B
est: 38.84B (-10.1%)
|
38.93B
est: 41.51B (-6.2%)
|
46.39B
44.86B – 46.93B
+11.8% YoY
|
49.28B
48.76B – 50.07B
+6.2% YoY
|
51.40B
48.36B – 55.37B
+4.3% YoY
|
54.90B
52.95B – 57.50B
+6.8% YoY
|
57.88B
55.83B – 60.63B
+5.4% YoY
|
| EPS |
113.99
est: 115.65 (-1.4%)
|
143.37
est: 144.38 (-0.7%)
|
156.97
est: 150.83 (+4.1%)
|
180.29
est: 184.20 (-2.1%)
|
197.67
est: 202.49 (-2.4%)
|
210.08
est: 207.21 (+1.4%)
|
231.73
est: 224.44 (+3.2%)
|
271.88
est: 266.01 (+2.2%)
|
291.36
est: 300.15 (-2.9%)
|
272.82
est: 268.98 (+1.4%)
|
313.26
est: 302.58 (+3.5%)
|
350.90
332.25 – 373.19
+16.0% YoY
|
373.60
368.97 – 376.05
+6.5% YoY
|
398.27
373.75 – 436.43
+6.6% YoY
|
463.70
442.29 – 492.29
+16.4% YoY
|
484.10
461.75 – 513.95
+4.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kojiro Kinoshita | Chairman & Chief Executive Officer | 90M | male |
| Shinsuke Yagi | President, Chief Operating Officer & Representative Director | 90M | male |
| Motoaki Ishikawa | Senior Managing Executive Officer, Head of Performance Materials Division & Director | — | male |
| Norihisa Ishiwata | Executive Officer & Head of Health Care Division | — | — |
| Satoshi Kageshima | Senior Executive Officer & Head of Intellectual Property Dept. | — | — |
| Takayasu Nihira | Managing Executive Officer, Head of Planning & Development Div. and Chief Technology Officer | — | — |
| Takeshi Matsuoka | Managing Executive Officer, CRO, Head of Corporate Planning Department & Director | — | male |
| Toshiaki Okikawa | Executive Officer & Head of Chemicals Division | — | — |
| Toshio Niki | Executive Officer & Head of Biological Research Laboratories | — | — |
| Toshiyuki Hata | Managing Executive Officer and Head of Production Technology Dept. & Production Technology | — | — |
| Wataru Kawashima | Executive Officer, Head of Personnel Dept. & GM of Health Promotion Office | — | — |
| Yuji Nishida | Executive Officer & Plant Manager of Toyama Plant | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4021.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
